-
Something wrong with this record ?
Reimbursed medication adherence enhancing interventions in 12 european countries: Current state of the art and future challenges
P. Kardas, M. Bago, P. Barnestein-Fonseca, K. Garuolienė, AG. Granas, J. Gregório, MO. Hadžiabdić, B. Kostalova, F. Leiva-Fernández, P. Lewek, K. Mala-Ladova, MP. Schneider, JFM. van Boven, D. Volmer, I. Ziampara, T. Ágh
Language English Country Switzerland
Document type Journal Article, Review
NLK
Directory of Open Access Journals
from 2010
Free Medical Journals
from 2010
PubMed Central
from 2010
Europe PubMed Central
from 2010
Open Access Digital Library
from 2010-01-01
Open Access Digital Library
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2010
- Publication type
- Journal Article MeSH
- Review MeSH
Background: Medication non-adherence jeopardises the effectiveness of chronic therapies and negatively affects financial sustainability of healthcare systems. Available medication adherence-enhancing interventions (MAEIs) are utilised infrequently, and even more rarely reimbursed. The aim of this paper was to review reimbursed MAEIs across selected European countries. Methods: Data on reimbursed MAEIs were collected from European countries at the ENABLE Cost Action expert meeting in September 2021. The identified MAEIs were analysed and clustered according to their characteristics, direct vs. indirect relation to adherence, and the targeted adherence phase. Results: Out of 12 contributing countries, 10 reported reimbursed MAEIs, 28 in total, of which 20 were identified as MAEIs targeting adherence directly. Reimbursed MAEIs were most often performed by either doctors (n = 6), nurses (n = 6), or pharmacists (n = 3). The most common types of MAEIs were education (n = 6), medication regimen management (n = 5), and adherence monitoring feedback (n = 4). Only seven reimbursed MAEIs were technology-mediated, whereas 11 addressed two interlinked phases of medication adherence, i.e., implementation and persistence. Conclusion: Our review highlights the scarcity of reimbursed MAEIs across the selected European countries, and calls for their more frequent use and reimbursement.
Centre for Applied Pharmacy Faculty of Pharmacy and Biochemistry University of Zagreb Zagreb Croatia
CUDECA Institute for Training and Research in Palliative Care CUDECA Hospice Foundation Málaga Spain
Faculty of Medicine Institute of Pharmacy University of Tartu Tartu Estonia
Health Insurance Organization National Health Insurance System Nicosia Cyprus
Institute of Pharmaceutical Sciences of Western Switzerland University of Geneva Geneva Switzerland
Norwegian Centre for E health Research University Hospital of North Norway Tromsø Norway
School of Pharmaceutical Sciences University of Geneva Geneva Switzerland
Section for Pharmaceutics and Social Pharmacy Department of Pharmacy University of Oslo Oslo Norway
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22023546
- 003
- CZ-PrNML
- 005
- 20221031095240.0
- 007
- ta
- 008
- 221010s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fphar.2022.944829 $2 doi
- 035 __
- $a (PubMed)36034792
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Kardas, Przemysław $u Medication Adherence Research Centre, Department of Family Medicine, Medical University of Lodz, Lodz, Poland
- 245 10
- $a Reimbursed medication adherence enhancing interventions in 12 european countries: Current state of the art and future challenges / $c P. Kardas, M. Bago, P. Barnestein-Fonseca, K. Garuolienė, AG. Granas, J. Gregório, MO. Hadžiabdić, B. Kostalova, F. Leiva-Fernández, P. Lewek, K. Mala-Ladova, MP. Schneider, JFM. van Boven, D. Volmer, I. Ziampara, T. Ágh
- 520 9_
- $a Background: Medication non-adherence jeopardises the effectiveness of chronic therapies and negatively affects financial sustainability of healthcare systems. Available medication adherence-enhancing interventions (MAEIs) are utilised infrequently, and even more rarely reimbursed. The aim of this paper was to review reimbursed MAEIs across selected European countries. Methods: Data on reimbursed MAEIs were collected from European countries at the ENABLE Cost Action expert meeting in September 2021. The identified MAEIs were analysed and clustered according to their characteristics, direct vs. indirect relation to adherence, and the targeted adherence phase. Results: Out of 12 contributing countries, 10 reported reimbursed MAEIs, 28 in total, of which 20 were identified as MAEIs targeting adherence directly. Reimbursed MAEIs were most often performed by either doctors (n = 6), nurses (n = 6), or pharmacists (n = 3). The most common types of MAEIs were education (n = 6), medication regimen management (n = 5), and adherence monitoring feedback (n = 4). Only seven reimbursed MAEIs were technology-mediated, whereas 11 addressed two interlinked phases of medication adherence, i.e., implementation and persistence. Conclusion: Our review highlights the scarcity of reimbursed MAEIs across the selected European countries, and calls for their more frequent use and reimbursement.
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Bago, Martina $u Reference Center of Pharmacoepidemiology, Research and Teaching Department, Andrija Stampar Teaching Institute of Public Health, Zagreb, Croatia
- 700 1_
- $a Barnestein-Fonseca, Pilar $u CUDECA Institute for Training and Research in Palliative Care, CUDECA Hospice Foundation, Málaga, Spain; Instituto de Investigación Biomédica de Málaga-IBIMA Group C08: Pharma Economy: Clinical and Economic Evaluation of Medication and Palliative Care, Málaga, Spain
- 700 1_
- $a Garuolienė, Kristina $u Pharmacy Center, Institute of Biomedical Science, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
- 700 1_
- $a Granas, Anne Gerd $u Section for Pharmaceutics and Social Pharmacy, Department of Pharmacy, University of Oslo, Oslo, Norway $u Norwegian Centre for E-health Research, University Hospital of North Norway, Tromsø, Norway
- 700 1_
- $a Gregório, João $u CBIOS - Universidade Lusófona's Research Center for Biosciences and Health Technologies, Lisbon, Portugal
- 700 1_
- $a Hadžiabdić, Maja Ortner $u Centre for Applied Pharmacy, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia
- 700 1_
- $a Kostalova, Barbora $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Leiva-Fernández, Francisca $u Multiprofessional Teaching Unit of Community and Family Care Primary Care District Málaga-Guadalhorce, Andalusian Health Service (SAS), Instituto de Investigación Biomédica de Málaga-IBIMA Group C08, Málaga, Spain
- 700 1_
- $a Lewek, Pawel $u Medication Adherence Research Centre, Department of Family Medicine, Medical University of Lodz, Lodz, Poland
- 700 1_
- $a Mala-Ladova, Katerina $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Schneider, Marie Paule $u School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland $u Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland
- 700 1_
- $a van Boven, Job F M $u Department of Clinical Pharmacy and Pharmacology, Medication Adherence Expertise Center of the Northern Netherlands (MAECON), University Medical Center Groningen, University of Groningen, Groningen, Netherlands
- 700 1_
- $a Volmer, Daisy $u Faculty of Medicine, Institute of Pharmacy, University of Tartu, Tartu, Estonia
- 700 1_
- $a Ziampara, Ioli $u Health Insurance Organization, National Health Insurance System, Nicosia, Cyprus
- 700 1_
- $a Ágh, Tamás $u Syreon Research Institute, Budapest, Hungary $u Center for Health Technology Assessment and Pharmacoeconomic Research, University of Pécs, Pécs, Hungary
- 773 0_
- $w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 13, č. - (2022), s. 944829
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36034792 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20221010 $b ABA008
- 991 __
- $a 20221031095237 $b ABA008
- 999 __
- $a ind $b bmc $g 1853914 $s 1174834
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 13 $c - $d 944829 $e 20220811 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
- LZP __
- $a Pubmed-20221010
